AstraZeneca: Lost Stock or Cheap Turnaround?
AstraZeneca may pay a heft dividend, but the company has been facing a number of headwinds and regulatory setbacks lately. In the following video from the Motley Fool's health-care show, Market Checkup, analysts David Williamson and Max Macaluso discuss the partnerships that this company has been forming to boost its pipeline and the key to accelerating its turnaround.
9 rock-solid dividends
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article AstraZeneca: Lost Stock or Cheap Turnaround? originally appeared on Fool.com.David Williamson and Max Macaluso, Ph.D. have no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.